UNICREDIT BANK/CALL/AMGEN/250/0.1/18.12.24 | Real-time BOERSE MUENCHEN 11:41:16 2024-06-27 am EDT | ||
| 6.67 EUR | +1.52% |
|
| Current month | +11.93% | ||
| 1 month | +8.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 6.67 | +1.52% |
| 24-06-26 | 6.57 | -7.46% |
| 24-06-25 | 7.1 | +3.95% |
| 24-06-24 | 6.83 | +7.73% |
| 24-06-21 | 6.34 | +1.44% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 11:41 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3JAJ |
| ISIN | DE000HC3JAJ4 |
| Date issued | 2023-01-26 |
| Strike | 250 $ |
| Maturity | 2024-12-18 (174 Days) |
| Parity | 10 : 1 |
| Emission price | 3.78 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.04 € |
|---|---|
| Lowest since issue | 1.33 € |
| Spread | 0.02 € |
| Spread % | 0.30% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.8
USD
Average target price
316.4
USD
Spread / Average Target
+1.16%
- Stock Market
- Warrants
- Warrant
